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Background/aim: The association between polymorphisms of xenobiotic/drug metabolizing enzymes and TP53 and response to
chemotherapy and survival of patients with nonsmall cell lung cancer (NSCLC) are limited and inconclusive. In this study, CYP2E1*5B,
CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and
survival in 137 advanced stage NSCLC patients were investigated.
Materials and methods: Genetic polymorphism analyses were determined by polymerase chain reaction (PCR) coupled with restriction
fragment length polymorphism (RFLP).
Results: The patients with TP53 Pro/Pro variant were more likely to be resistant to chemotherapy than those with Arg/Arg variants with
marginal significance (P = 0.066). We also analyzed these gene variants in combination with CYP1A1 (Ile462Val), CYP1B1 (Asn453Ser),
GSTM1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) and GSTT1 polymorphic genes that we have previously genotyped
in the same patients (Ada et al., Neoplasma, 57, 512-527, 2010). The multivariate analysis revealed that adjusted hazard ratio (HR) of
death of the combined variant genotypes of TP53 (Arg72Pro, Pro72Pro) and CYP1A1 (Ile462Val, Val462Val) increased significantly as
compared to wild-type genotypes (HR, 6.03; 95% CI, 1.39–26.04, P = 0.016).
Conclusion: These results show that combined variant genotypes of TP53 (Arg72Pro, Pro72Pro) and CYP1A1 (Ile/Val, Val/Val) are
associated with worsening of survival in NSCLC patients.
Key words: Xenobiotic/drug metabolizing enzymes, TP53, polymorphisms, response to chemotherapy, survival, nonsmall cell lung cancer

1. Introduction
Lung cancer is the worldwide leading cause of cancer
mortality (1). Nonsmall cell lung cancer (NSCLC)
patients represent the majority of lung cancer cases and
they are mainly treated with standard platinum-based
chemotherapy (2). However, the poor response and a great
interindividual variety in response to this chemotherapy
treatment occur among these patients (3). Thus, the
reasons behind the failure and interindividual variety
of response to chemotherapy and thus possibly poorer
survival in these patients are very important.
The majority of lung cancer patients are smokers (4).
Cigarette smoke is known to increase the carcinogen
DNA-adduct levels, which in turn form aggressive tumors
* Correspondence: iscan@pharmacy.ankara.edu.tr
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by mutating and thus inactivating tumor suppressor genes,
such as TP53, and thereby decrease the survival rates of
patients with NSCLC (5,6).
Metabolic activation of N-nitrosamines such as
nicotine-derived nitrosamine ketone (NNK), benzene,
and vinyl chloride in cigarette smoke to mutagenic and
carcinogenic metabolites are mediated by CYP2E1 (7). In
addition, CYP2E1 also plays a role in the metabolism of a
number of chemotherapeutic agents and thus is involved
in drug resistance (8). The expression of CYP2E1 has also
been found to be increased in lung cancer (9,10). The
most common alleles and polymorphisms of CYP2E1
are CYP2E1*5B (RsaI/PstI C1053T/C1293C) (11,12)
and CYP2E1*6 (DraI T7632A) (13). The variant alleles
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have been shown to lower activities of the corresponding
enzymes (11,12). In addition, the CYP2E1 gene has also
the CYP2E1*7B allele (14) but no information is available
on its possible activity alteration. Several studies have
also shown the existence of an association between lung
cancer and CYP2E1*5B (15,16) and CYP2E1*6 (13,15)
polymorphisms in various populations.
On the other hand, one of the members of glutathione
S-transferase (GST) family, GST Omega 1 (GSTO1),
plays a role in apoptosis (17) and is a potential reservoir
of intracellular glutathione (GSH), which protects against
cellular oxidative stress (18). The protective role against cell
toxicity can be weakened if the enzyme activity is reduced,
but the findings related to the GSTO1 gene polymorphism
Ala140Asp (A140D) are still inconclusive (19,20). Recent
studies have established an association between the GSTO1
(A140D) gene polymorphism and increased risk of several
carcinomas such as breast and hepatocellular carcinoma
(21) but not with lung or colorectal cancers (21,22).
The TP53 gene is a well-known tumor suppressor gene
that regulates cell-cycle arrest, DNA repair, and apoptosis
in response to cellular stress including chemotherapy
(23). Thus, normal activity of TP53 is necessary for the
sensitivity of the cancer cells to chemotherapeutics and
thus the inhibition of TP53 can lead to chemoresistance
(24). Tobacco-specific carcinogenic compounds have
also been shown to cause mutations in the TP53 gene
(25). Several functional SNPs occur in the TP53 gene and
the most frequently studied is the polymorphism TP53
(Arg72Pro), the variant allele being altered, decreasing
the TP53 activity in apoptosis (26,27). Emerging
evidence, although inconclusive, has shown that TP53
(Arg72Pro) polymorphism is not only associated with
lung cancer risk but also influences patient response to
platinum-based chemotherapy and survival (28–33).
Furthermore, associations have also been shown between
polymorphisms of some CYP genes such as the CYP2E1 or
CYP1A1 and TP53 gene in NSCLC (5,6,9,34,35).
All this information is necessary and important in
terms of determining the predictive and prognostic
significances of these genotypes of NSCLC patients,
leading to the availability of the tool needed by clinicians
to individualize therapies and accurately predict survival.
However, a limited number of molecular epidemiological
studies, with controversial results, to date have considered
determining the role of CYP2E1*5B (34–36), CYP2E1*6
(37), and TP53 (Arg72Pro) (28–31,38,39) polymorphisms
in this regard. In addition, to the best of our knowledge,
no information is available with respect to CYP2E1*7B
and GSTO1 (A140D) polymorphisms and their overall
combined impact on clinical outcome in NSCLC.
In the present study, we aimed to determine the
association either alone or in combination between the

CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D),
and TP53 (Arg72Pro) polymorphisms and response to
platinum-based chemotherapy and survival in advanced
stage NSCLC patients. Given the complexity of the
pathways of drugs/pro-carcinogens and the possible
interactions between encoding activation/inactivation
enzymes and TP53 protein that might have cooperative
impact on outcome of NSCLC patients treated with
platinum-based chemotherapy, we further analyzed the
possible interactions combining these gene polymorphisms
with CYP1A1 (Ile462Val), CYP1B1 (Asn453Ser), GSTM1,
GSTP1 (Ile105Val), GSTP1 (Ala114Val), and GSTT1 gene
polymorphisms that we previously genotyped in the same
patients (40).
2. Materials and methods
2.1. Patients
In total, 137 patients of mean age 56 ± 9 (mean ± SD;
range: 34–75) who had a histological diagnosis of primary
NSCLC with stages III or IV and who were treated with
platinum-based chemotherapy were enrolled in this
study; 125 of these patients were male, with a mean age
of 56 ± 9 (mean ± SD; range: 34–75), and 12 were female,
with a mean age of 58 ± 8 (mean ± SD; range: 44–69).
All patients were recruited from Atatürk Pulmonary
Diseases and Thoracic Surgery Hospital from February
2002 to November 2005. All patients provided written
informed consent and the study was approved by the
Medical Ethics Board of Atatürk Pulmonary Diseases and
Thoracic Surgery Hospital. Clinical information and the
chemotherapy regimen of patients and the evaluation of
the effect of chemotherapy have been described in detail
elsewhere (40,41). The responder group consisted of
patients with complete response (CR) and partial response
(PR) and the nonresponsive group consisted of patients
with stable disease (SD) and progressive disease (PD).
2.2. Genotyping procedure
Lymphocyte DNA was isolated from the patients using
a Promega genomic DNA purification kit (Promega,
Madison, WI, USA) according to the manufacturer’s
instructions. Genetic polymorphism analyses were
conducted by PCR-RFLP method. PCR master mixes were
obtained from Qiagen (Hilden, Germany). Restriction
enzymes were purchased from NEB (Ipswich, MA,
USA). CYP2E1*5B polymorphism was determined by the
method of Hayashi et al. (11). CYP2E1*6 polymorphism
was determined by the method of Kato et al. (42).
CYP2E1*7B polymorphism was determined using the
method of Yang et al. (43). Genetic polymorphism analysis
for the GSTO1 (A140D) was determined by the method
described by Marahatta et al. (21). The TP53 (Arg72 Pro)
gene polymorphism was determined by the method of Hu
et al. (30). For quality control, the laboratory personnel

555

KARACAOĞLAN et al. / Turk J Med Sci
were blinded to the source of each DNA specimen and
a random 10% of the samples were repeated with 100%
concordance. Two authors reviewed independently 100%
of the agarose gels and genotype data entry.
2.3. Statistical analysis
Chi-square analysis and Fisher’s exact tests were used to
compare the distribution of genotypes between subgroups
and response to chemotherapy. We calculated survival
as the period from diagnosis to the date of death or the
date of last follow-up for each patient. Overall survival in
relation to CYP, GST, and TP53 genotypes was evaluated
by the Kaplan–Meier survival function and log-rank tests.
Hazard ratios (HRs) were estimated from a multivariate
Cox proportional hazards model with adjustment for age,
sex, smoking status, chemotherapy regimen, tumor stage,
and tumor histology. Only P values < 0.05 were considered
significant. SPSS (SPSS, Inc., Chicago, IL, USA) was used
for the statistical analysis.

3. Results
Characteristics of the 137 patients at diagnosis are
provided in Table 1. Among the 137 patients, 42 (31%)
of them responded to the platinum-based first-line
chemotherapy, whereas 95 (69%) of them did not. When
the distributions of response to chemotherapy according
to patient characteristics were evaluated they were not
found to be related to age, sex, tumor histology, stage at
diagnosis, chemotherapy regimen, or smoking status (P >
0.05, data not shown).
The distributions of the genotypes (either alone or in
combination) according to patient characteristics were
also evaluated and were not observed to be related to age,
sex, tumor histology, stage at diagnosis, or smoking status
(P > 0.05, data not shown).
Although no significant associations were noted
between the gene polymorphisms alone or in combination
and response to chemotherapy, patients with the TP53

Table 1. Characteristics of 137 NSCLC patients.
Characteristics

Number of patients

Total

137

Age
≤50

40

51–60

47

≥61

50

Male

125

Female

12

Sex

Histology
Squamous cell carcinoma

49

Adenocarcinoma

48

Unspecified nonsmall cell lung cancer

40

Stage at diagnosis
Stage III

60

Stage IV

77

Chemotherapy

a

Platinum + Etoposideb

86

Platinum + othersc

51

Smoking status
Never

13

Current

85

Former

39

The chemotherapy regimens are detailed previously (40)
Cisplatin + Etoposide
c
Cisplatin + Gemcitabine, Cisplatin + Docetaxel, Cisplatin + Vinoralbine,
Cisplatin + Paclitaxel, Carboplatin + Paclitaxel
a

b
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Pro/Pro variant were more likely to be resistant to
chemotherapy than those with Arg/Arg variants (100%
vs. 66%) or with Arg/Arg and Arg/Pro variants (100%
vs. 68%), with marginal significance (P = 0.066 and P =
0.071, respectively) (Table 2). No significant associations
were noted between the responses of the genotypes (either
alone or in combination) and age, sex, smoking status,
chemotherapy regimen, tumor stage, or histology (P >
0.05, data not shown).
The Kaplan–Meier survival functions for overall
survival according to the genotypes (either alone or in
combination) were analyzed. In total, 58 (42%) deaths
were observed during follow-up. Among the genotypes
either alone or in combination, there was no significant
association between CYP2E1, GSTO1 (A140D), and TP53
genotypes and Kaplan–Meier function survival rates (P >
0.05, data not shown). We also investigated the possible
interactions for combining these genes with polymorphic
genes of CYPs (CYP1A1 and CYP1B1) and GSTs (GSTM1,
GSTP1, and GSTT1) that we previously genotyped in these
patients (40). However, while in the previous study (40)
the number of the patients was 138, in the present study
the number of patients enrolled was 137. We enrolled
137 patients because one patient’s DNA had run out.
Therefore, we statistically recalculated the parameters of
137 patients of the previous study, excluding the patient’s
data whose DNA had finished. No significant associations
were noted between the combined genotypes and
responses to chemotherapy. However, only two of them
revealed a remarkably altered survival period. The patients
who had both variant genotypes of TP53 (Arg/Pro, Pro/
Pro) and CYP1A1 (Ile/Val, Val/Val) had shorter survival
(median, 15.6 months) compared to those with wild-type
genotypes (median, 19.4 months) (P = 0.480) (data not
shown). Likewise, the patients who had variant genotypes
of both TP53 (Arg/Pro, Pro/Pro) and GSTO1 (A/D, D/D)
had shorter survival (median, 18.4 months) compared to
those with wild-type genotypes (median, 22.7 months) (P
= 0.560) (data not shown).

The distributions of CYP2E1, GSTO1, and TP53
genotypes (either alone or in combinations) and survival of
the NSCLC patients are shown in Tables 3 and 4. However,
due to the very limited number of patients with null and/
or variant genotypes, only the genotype combinations that
were available for statistical analysis are given in Table 4.
Overall multivariate analysis revealed no significant HR of
death associated with the genotype combinations. When
we analyzed the possible interactions combining these gene
polymorphisms with CYP and GST gene polymorphisms
that we previously genotyped in the same patients (40),
one of the genotype combinations showed a remarkably
significant association with HR of death. The death risk
of combined variant genotypes of TP53 (Arg/Pro, Pro/
Pro) and CYP1A1 (Ile/Val, Val/Val) increased significantly
as compared to wild-type genotypes (HR, 6.03; 95% CI,
1.39–26.04, P = 0.016) (Table 4). The other genotype
combinations that showed remarkable but not significant
increases in HR of death were CYP2E1*7B (*1A/*7B) and
TP53 (Arg/Pro, Pro/Pro) (HR, 2.70; 95% CI, 0.80–9.08, P
= 0.108) and GSTO1 (A/D, D/D) and TP53 (Arg/Pro, Pro/
Pro) (HR, 2.52; 95% CI, 0.75–8.49, P = 0.137).
4. Discussion
To the best of our knowledge this is the first study
investigating the joint effect of TP53 (Arg72Pro) and
the aforementioned CYP and GST polymorphisms on
the clinical outcome of NSCLC patients with platinumbased chemotherapy. In the current study, we found that
the TP53 Pro/Pro genotype was likely to be resistant to
platinum-based chemotherapy, with marginal significance
(P = 0.066), but unlikely to predict the survival. Our data
also indicated that the combined polymorphisms of TP53
(Arg72Pro) and CYP1A1 (Ile 462Val) were likely to play
a role in the prognosis of NSCLC patients treated with
platinum-based chemotherapy.
In regard to CYP2E1 polymorphisms and survival in lung
cancer, only a few studies exist and their results are rather
contradictory. For example, the studies on CYP2E1*5B

Table 2. The distributions of TP53 genotypes according to response to chemotherapy.
Response to chemotherapy
Genotype

Responder

Nonresponder

P-value

TP53 (Arg72Arg)

14

27

0.066

TP53 (Pro72Pro)

0

7

TP53 (Arg72Arg + Arg72Pro)

42

88

TP53 (Pro72Pro)

0

7

TP53 (Arg72Arg)

14

27

TP53 (Arg72Pro + Pro72Pro)

28

68

0.071
0.563
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Table 3. CYP, GST, and TP53 genotypes (alone) and survival of NSCLC
patients.
Overall survival
Genotype

n

HR (95% CI)a

CYP2E1*5B (*1A/*1A)

132

1

CYP2E1*5B (*1A/*5B)

5

1.23 (0.25–6.06)

CYP2E1*6 (*1A/*1A)

121

1

CYP2E1*6 (*1A/*6)

16

1.36 (0.63–2.92)

CYP2E1*7B (*1A/*1A)

124

1

CYP2E1*7B(*1A/*7B)

13

1.02 (0.41–2.53)

GSTO1 (A/A)

70

1

GSTO1 (A/D+D/D)

67

1.04 (0.65–1.66)

TP53 (Arg/Arg)

41

1

TP53 (Arg/Pro)

89

1.27 (0.02–2.57)

TP53 (Arg/Arg)

41

1

TP53 (Pro/Pro)

7

0.22 (0.69–3.07)

TP53 (Arg/Arg)

41

1

TP53 (Arg/Pro+Pro/Pro)

96

1.14 (0.62–2.11)

P-value
0.801
0.432
0.958
0.875
0.226
0.318
0.667

a
HR: hazard ratio, 95% CI: 95% confidence interval.
Variant genotype compared to wild-type genotype. HR and 95% CI values were
determined by using Cox proportional hazards model that was adjusted for
age, sex, tumor histology, tumor stage, smoking status, chemotherapy regimen,
and response to chemotherapy.

are rather conflicting. While Oyama et al. (35) found an
increase in survival in mutant allele carriers, Haque et al.
(34) observed a shorter survival in mutant carriers and Li
et al. (36) did not find any association between this CYP
gene polymorphism and survival in NSCLC. Przygodzki et
al. (37) could not find any significant association between
CYP2E1*6 polymorphisms and survival in NSCLC
patients. Moreover, almost no information is available with
respect to the relationship between these polymorphisms
and response to chemotherapy in NSCLC patients. The
only data in this regard were recently provided by Li et
al. (36), who did not observe any significant association
between CYP2E1*5B polymorphism and response to
chemotherapy in NSCLC. Thus, based on the previously
reported results on CYP2E1*5B, our results are in line
with the findings given by Li et al. (36) in regard to both
response to chemotherapy and survival but in contrast
to those of Oyama et al. (35) and Haque et al. (34) in
respect to survival. Our findings in regard to CYP2E1*6
polymorphisms on survival also coincided with the results
of Przygodzki et al. (37). The CYP2E1*7B polymorphism
appeared to have no effect on the prognosis of NSCLC.
The studied CYP2E1 polymorphisms either alone or in
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combination are unlikely to a play role in the prognosis
of NSCLC. The reasons for the inconsistent results of
the CYP2E1*5B polymorphism on survival among these
studies remain to be explored in further studies.
Previous reports suggested that GSTO1 (A140D)
polymorphisms might be associated with lung cancer
in smokers (44,45). However, we could not find any
association in our Turkish population (22). In the current
study, GSTO1 (A140D) polymorphism alone has been
shown to have no effect on NSCLC prognosis.
The 72 Pro variant was shown to have less apoptotic
potential than the 72Arg, rendering this polymorphism
one of the most frequently studied variations in the
P53 pathway (26,27). Although TP53 (Arg72Pro)
polymorphism has been shown to affect the prognosis
of various cancers (46,47), findings for NSCLC is still
inconclusive and controversial (28–31,38,39). Our findings
with respect to resistance to chemotherapy are similar to
the results of the study by Han et al. (29), who observed
the variant allele was resistant to first-line chemotherapy
in NSCLC. Among our nonresponsive patients carrying
the 72 Pro variant allele, 3 of them were treated with
platinum and etoposide and 4 of them were treated with
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Table 4. CYP, GST, and TP53 genotypes (in combination) and survival of NSCLC patients.
Overall survival
Genotype

n

HR (95% CI)a

CYP2E1*5B (*1A/*1A)+TP53 (Arg/Arg)

39

1

CYP2E1*5B (*1A/*5B)+TP53 (Arg/Pro+Pro/Pro)

3

1.73 (0.16–18.53)

CYP2E1*6 (*1A/*1A)+TP53 (Arg/Arg)

37

1

CYP2E1*6 (*1A/*6) +TP53 (Arg/Pro+Pro/Pro)

12

1.81 (0.54–6.06)

CYP2E1*7B (*1A/*1A)+TP53 (Arg/Arg)

40

1

CYP2E1*7B(*1A/*7B) +TP53 (Arg/Pro+Pro/Pro)

12

2.70 (0.80–9.08)

GSTO1 (A/A) + TP53 (Arg/Arg)

17

1

GSTO1 (A/D+D/D) + TP53(Arg/Pro+Pro/Pro)

43

2.52 (0.75–8.49)

TP53 (Arg/Arg) + CYP1A1 (Ile/Ile)

31

1

TP53 (Arg/Pro+Pro/Pro) + CYP1A1 (Ile/Val+Val/Val)

14

6.03 (1.39–26.04)

TP53 (Arg/Arg) + CYP1B1 (Asn/Asn)

26

1

TP53 (Arg/Pro+Pro/Pro) + CYP1B1 (Asn/Ser+Ser/Ser)

27

1.22 (0.45–3.28)

TP53 (Arg/Arg) + GSTM1 positive

17

1

TP53 (Arg/Pro+Pro/Pro) + GSTM1 null

56

0.90 (0.34–2.37)

TP53 (Arg/Arg) + GSTT1 positive

29

1

TP53 (Arg/Pro+Pro/Pro) + GSTT1 null

25

1.72 (0.52–5.62)

TP53 (Arg/Arg) + GSTP1 exon 5 (Ile/Ile)

24

1

TP53 (Arg/Pro+Pro/Pro) + GSTP1 exon 5 (Ile/Val+Val/Val)

34

1.40 (0.51–3.83)

TP53 (Arg/Arg) + GSTP1 exon 6 (Ala/Ala)

30

1

TP53 (Arg/Pro+Pro/Pro) +GSTP1 exon 6 (Ala/Val+Val/Val)

19

0.65 (0.16–2.73)

P-value
0.649
0.336
0.108
0.137
0.016
0.695
0.834
0.371
0.513
0.562

HR: hazard ratio, 95% CI: 95% confidence interval.
Null or variant genotype compared to present or wild-type genotype. HR and 95% CI values were determined by
using Cox proportional hazards model that was adjusted for age, sex, tumor histology, tumor stage, smoking status,
chemotherapy regimen, and response to chemotherapy.
a

platinum and other chemotherapeutics. In the study by
Han et al. (29), the nonresponsive patients carrying the
72 Pro variant allele were resistant to an irinotecan plus
cisplatin regimen. These findings seem to reveal that
this polymorphism is predictive for primary resistance
especially to these chemotherapeutic drugs.
With respect to overall survival our results are in line
with the findings of several investigators (28–30,38) while
in contrast to those of others (31,39). At this stage, the
reasons for the inconsistent results among all these studies,
including ours, are not clear. Nevertheless, methodological
and statistical discrepancies may, in part, account for the
lack of consistent findings.
On the other hand, the lack of association between
CYP2E1 or GSTO1 genotypes and response to
chemotherapy observed in the current study is likely to
show that these polymorphisms are not functioning as
a predictor of response to these two distinct platinum-

based chemotherapy regimens (platinum and etoposide or
platinum and other chemotherapeutics).
Recent studies have demonstrated that the
simultaneous analysis of such gene polymorphisms may
correlate well with the clinical outcome better than the
single polymorphism studies. For example, the combined
variant CYP1A1 (Ile462Val) and GSTM1 null genotype
was associated with better response to chemotherapy but
not with survival in lung cancer (36). Our previous study
in NSCLC patients also revealed CYP1A1 and GSTP1 exon
5 variant alleles or CYP1B1 and GSTP1 exon 5 variant
alleles had notable trends toward worsening of survival,
whereas better survival was noted with combined GSTP1
exon 5 and GSTP1 exon 6 variant alleles (40).
In the present study, the combined variant genotypes
of TP53 (Arg/Pro, Pro/Pro) and CYP1A1 (Ile/Val, Val/
Val) were determined to play a role in the prognosis, a
prognostic of worse survival, in patients with advanced
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NSCLC. Likewise, previous studies demonstrated that
CYP1A1gene Msp1 mutation carrier NSCLC patients
had higher rates of TP53 mutations and variant allele
carriers of the CYP1A1 (Msp1) gene had shorter survival
compared to those of wild-type genotypes in advanced
NSCLC (5,6,10,35). The variant alleles of CYP1A1 such
as CYP1A1*2A (Msp1) and CYP1A1*2C (Ile462Val) have
higher enzyme activities (48,49). Positive associations
have also been observed between these polymorphisms
and benzo(a)pyrene 7,8-9,10 diol epoxide (BaPDE)-DNA
adduct levels in the lungs of smokers or increase in cancer
risk in various populations (15,50). Thus, the observed
finding seems to be conceivable as the CYP1A1*2C gene
variant elevates enzyme activity, which leads to more
tobacco-specific PAH-activated carcinogenic/mutagenic
e.g. BaPDE-DNA adducts, which in turn cause the
formation of aggressive tumors by mutating and thus

inactivating tumor suppressor gene TP53, and thereby
decreasing the survival rates of patients with NSCLC. In
addition, in the current study, the combined CYP2E1*7B
and TP53 variant alleles and GSTO1 and TP53 variant
alleles demonstrated notable trends toward worsening
survival.
In summary we have demonstrated that the combined
variant genotypes of TP53 (Arg/Pro, Pro/Pro) and CYP1A1
(Ile/Val, Val/Val) are associated with worsening survival in
advanced NSCLC patients treated with platinum-based
chemotherapy. However, additional studies are required to
confirm our finding.
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